উ:/...KIR/9201A4/9201A4.SSI HL22/wp7 DEB/CSE/HL/dcm 07/14/98



DECKET NO.: KIR92-01

IN THE UNITE PATENT AND TRADEMARK OFFICE

Applicants	٠

Marc Feldmann and Ravinder N. Maini

Application No.:

08/690,775

Group Art Unit: 1642

Filed:

August 1, 1996

Examiner: P. Gambel

Title:

(Filed after payment of issue fee)

ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF **AUTOIMMUNE DISEASE**

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistaı	nt Commissioner for Patents	
Washin	gton, D.C. 20231	
O:		
Sir:		
This Inf	formation Disclosure Statement is submitted:	
[]	under 37 CFR 1.129(a), or	
	(First/Second submission after Final Rejection)	
[]	under 37 CFR 1.97(b), or	
	(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing d	ate of first office action on
	the merits; whichever occurs last)	0 5 7
		R F M
[X]	under 37 CFR 1.97(c) together with either:	21 0
	[X] a Statement under 37 CFR 1.97(e), as checked below, or	RECEIVED JUL 21 PMI2: 1 GROUP 180
	a \$240.00 fee under 37 CFR 1.17(p), or	080
	(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	- 5
[]	under 37 CFR 1.97(d) together with:	_
	[] a Statement under 37 CFR 1.97(e), as checked below, and	
	[] a Petition under 37 CFR 1.97(d)(2), and	
	[] a \$130.00 petition fee set forth in 37 CFR 1.17(i). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)	
[]	Applicant requests that the attached IDS and cited reference(s)be placed in the applicant requests.	cation filewrapper.

Statement Under 37 CFR 1.97(e)

[]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or		
[X]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		
Enclose	ed herewith is form PTO-1449:		
[X]	Copy of the cited reference (AL2) is enclosed.		
[]	Copies of cited references are enclosed except those entered in prior application, U.S. Serial No, and references that are not required to be submitted under 37 CFR 1.98.		
[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.		
Concise	e Explanation Requirement (non-English references):		
[].	The "concise explanation" requirement for reference(s) under 37 CFR 1.98(a)(3) is satisfied by:		
	[] the explanation provided on the attached sheet.		
	[] the explanation provided in the Specification.		
	[] submission of the enclosed International Search Report.		
	[] the enclosed English language abstract.		
It is req	uested that the information disclosed herein be made of record in this application.		
Method	of payment:		
[]	Enclosed is a check in the amount of \$		
[]	Please charge Deposit Account 08-0380 in the amount of \$		
[]	A copy of this Statement is enclosed.		
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.		
	Respectfully submitted,		
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.		

Helen Lee

Registration No.: 39,270 Telephone: (781) 861-6240 Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: guly 14,1998